INAB - IN8bio Inc
IEX Last Trade
0.5175
-0.002 -0.329%
Share volume: 59,401
Last Updated: Fri 30 Aug 2024 09:58:28 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.52
0.00
-0.33%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.61%
1 Month
-36.49%
3 Months
-48.89%
6 Months
-54.23%
1 Year
-52.58%
2 Year
-80.93%
Key data
Stock price
$0.52
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.50 - $2.48
52 WEEK CHANGE
-$0.50
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: William Ho
Region: US
Website: https://www.in8bio.com
Employees: 31
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.in8bio.com
Employees: 31
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.
Recent news